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Abstract 36 
 37 
Objective 38 
Motivated by recent calls to use electronic health records for research, we reviewed the application 39 
and development of methods for addressing the bias from unmeasured confounding in longitudinal 40 
data. 41 
 42 
Design 43 
Methodological review of existing literature 44 
 45 
Setting 46 
We searched MEDLINE and EMBASE for articles addressing the threat to causal inference from 47 
unmeasured confounding in nonrandomised longitudinal health data through quasi-experimental 48 
analysis. 49 
 50 
Results 51 
Among the 121 studies included for review, 84 used instrumental variable analysis (IVA), of which 52 
36 used lagged or historical instruments. Difference-in-differences (DiD) and fixed effects (FE) 53 
models were found in 29 studies. Five of these combined IVA with DiD or FE to try to mitigate for 54 
time-dependent confounding. Other less frequently used methods included prior event rate ratio 55 
adjustment, regression discontinuity nested within pre-post studies, propensity score calibration, 56 
perturbation analysis and negative control outcomes. 57 
 58 
Conclusions  59 
Well-established econometric methods such as DiD and IVA are commonly used to address 60 
unmeasured confounding in non-randomised, longitudinal studies, but researchers often fail to take 61 
full advantage of available longitudinal information. A range of promising new methods have been 62 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 3
developed, but further studies are needed to understand their relative performance in different 63 
contexts before they can be recommended for widespread use. 64 
 65 
Keywords: method review, unmeasured confounding, unobserved confounding, longitudinal, 66 
observational data, electronic health records 67 
 68 
Running title: Review of methods adjusting for unmeasured confounding in longitudinal data 69 
Word count: 199 70 
  71 
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  72 
 
What is new? 
What is already known 
• Unmeasured confounding is a threat to the validity of observational studies based on 
data from non-randomised longitudinal studies 
Key findings 
• Longitudinal information that can be used to mitigate for unmeasured confounding in 
observational data is not always fully or properly utilised in health research. 
• Instrumental variable analysis and difference-in-differences were the most commonly 
encountered methods to adjust for unmeasured confounding in a review of the health 
literature. 
• There are a range of promising new methods, some of which utilise longitudinal 
information to relax the assumption of time-invariance for unmeasured confounders, but 
these are yet to be widely adopted. 
What is the implication? 
• All available methods rely on strong assumptions and more research is needed to 
establish the relative performance of different methods for particular problems and 
empirical settings. 
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1 Introduction 73 
 74 
 75 
In the era of “big data” in medicine, the increasing availability of large, longitudinal patient 76 
databases is creating new opportunities for health researchers.  A particular focus is on electronic 77 
health records (EHR) with routinely collected data collated from multiple care sites, often linked to 78 
external databases (e.g. death certificates). Built up over time, EHRs provide a sequential history of 79 
each patient’s encounter with the healthcare system. Examples of EHRs include The Clinical 80 
Practice Research Datalink (CPRD), The Health Improvement Network (THIN), QResearch and 81 
ResearchOne in the UK, and the Kaiser Permanente Northern California Oracle Research Database 82 
in the US. The value of large medical data recorded for administrative purposes in national 83 
registries is already recognised 1,2, with the provision of funds to expand the adoption of EHRs in 84 
research for patient benefit in the US with the Health Information Technology for Economic and 85 
Clinical Health (HITECH) Act of 2009, and in the UK, with a consortium of funding bodies led by 86 
the Medical Research Council. Another important source of information for health care analysis is 87 
databases of insurance claims, such as Medicare in the US, and in this review we do not 88 
differentiate between EHRs and claims data. 89 
 90 
A strength of EHRs and claims data is that they make it possible to study the comparative 91 
effectiveness of interventions and the associated risk of side-effects in a real-world setting. 92 
Although randomised trials provide the gold standard of evidence, observational studies based on 93 
observational patient databases offer the potential to study more patients from a wider variety of 94 
risk groups with a longer follow-up period at a fraction of the cost. However, in the absence of 95 
randomisation, selection for treatment is often knowingly based on specific characteristics, such as 96 
frailty, disease severity or the risk of an outcome. If the indication for treatment is also related to 97 
prognosis, confounding by indication arises leading to biased estimation of effectiveness.  There is 98 
a large pharmacoepidemiologic literature on this topic and current best practice is to use design-99 
based approaches such as the Active Comparator, New User Design to help mitigate bias where 100 
possible3.However, residual differences between the treatment arms other than the treatment itself 101 
may still confound the intervention effect under study whether or not such an approach is used. If 102 
the confounding variables are both known to the study investigators and measurable, then these 103 
could potentially be adjusted for in prospective non-randomised studies. With retrospectively 104 
recruited subjects, however, the recording of such variables is outside the control of the 105 
investigator.  Analyses of non-randomised studies that fail to account for relevant confounders may 106 
have important negative consequences for health policy and patient safety. 107 
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 108 
Methods described as the quasi-experimental (QE) approach4, can be deployed to account for 109 
confounding by unobservable characteristics. These do not attempt to directly adjust for resulting 110 
bias, but use available information to achieve this indirectly under certain conditions and 111 
assumptions.  The aim of this systematic review is to review current practices in dealing with 112 
unmeasured confounding in individual-level longitudinal health data and to capture methodological 113 
developments in this area. While previous systematic reviews have been conducted to look at use 114 
of propensity score methods for measured confounders 5,6, we are unaware of any systematic 115 
review comparing use of methods for addressing unmeasured confounding in non-randomised, 116 
longitudinal data. We were particularly interested in how an individual’s history could be leveraged 117 
to evaluate the effects of unmeasured confounding and how the extra longitudinal information 118 
could be incorporated to improve adjustment for confounding bias. We intend for this review to 119 
contribute to the development of best practice in addressing unmeasured confounding in 120 
longitudinal data. The results should therefore help inform researchers intending to utilise “big 121 
data” from electronic health records. 122 
 123 
2 Methods 124 
 125 
2.1 Search strategy 126 
 127 
Our search strategy was informed by, but not limited to, known methods for addressing 128 
unmeasured confounding. The search strategy is recorded in Appendix A. The following electronic 129 
databases were searched: MEDLINE (via OvidSp including In-Process & Other Non-Indexed 130 
Citations) and EMBASE (via OvidSp 1996 to 2015 Week 21). We included all citation dates from 131 
database inception to May 2015. All references were exported into Endnote X7 (Thomson Reuters). 132 
 133 
2.2 Inclusion and exclusion criteria  134 
 135 
The review included any non-randomised comparative studies that sought to adjust for unmeasured 136 
confounding in longitudinal data with repeated observations on identifiable individuals. In the 137 
interests of good practice, eligible papers had to explicitly identify the problem of bias arising from 138 
the selection on unobservable characteristics in the data, rather than routinely apply a QE design 139 
without this justification. For estimates of comparative effectiveness, eligible studies had to have 140 
independent control arms for each treatment of interest. Therefore, single arm studies were 141 
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excluded. Studies based on case-only designs, including the case-crossover design and the self-142 
controlled case-series design, in which confounding is controlled by making comparisons between 143 
exposed and unexposed periods for the same individual were also excluded.  Observational studies 144 
were not excluded based on the exposure under study so studies into the effects of passive 145 
exposures (medical conditions, environmental exposures etc) were included alongside studies of 146 
both the intended and adverse effects of active interventions. We note that good proxies for 147 
unmeasured confounding, or observed variables that sufficiently describe a latent variable such as 148 
frailty, would be preferable to dealing with the bias resulting from unmeasured confounders. If 149 
suitable proxies are identified and recorded, then there are in effect no unobserved confounders and 150 
the proxies could simply be adjusted for in the analysis, obviating the need for methods to adjust 151 
for the unobserved confounders. For this reason, adjustments for proxies of unmeasured 152 
confounders, including high-dimensional propensity scores, did not fall within the scope of this 153 
study. To be consistent with the “big data” theme of EHRs, a minimum sample size of 1000 154 
participants was applied. This also set a minimum condition for the application of Instrumental 155 
Variable (IV) and Regression Discontinuity (RD) designs stipulated in the Quality of Effectiveness 156 
Estimates from Non-randomised Studies (QuEENS) checklist. Finally, we only accepted analyses 157 
of individual level data. We were aware that some studies may use analytical methods, such as 158 
difference-in-differences that aggregate the data at a treatment-group level. We therefore only 159 
included those studies, in which the same patients could be tracked over the time-frame of the 160 
sample. Conversely, some methods, such as instrumental variable analysis, make no explicit 161 
demands for longitudinal data at the patient level. However, we included such studies where the 162 
sample was based on the availability of patient-level longitudinal information, with a history 163 
possibly but not necessarily preceding the time of exposure. We did not discriminate between data 164 
sources, as patient-level data will often arise from medical insurance claims in the US, as opposed 165 
to clinically-purposed databases in other countries. 166 
Only studies written in English were included.  167 
 168 
The following publication types were excluded from the review: 169 
• systematic reviews of primary studies. 170 
• randomised controlled trials 171 
• cross-sectional data  172 
• preclinical and biological studies 173 
• narrative reviews, editorials, opinions 174 
 175 
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2.3 Study selection 176 
 177 
Studies retrieved from the searches were selected for inclusion through a two-stage process 178 
according to the inclusion/exclusion criteria specified above. First, abstracts and titles returned by 179 
the search strategy were screened for inclusion independently by two researchers. In case of doubt, 180 
the article in question was obtained and a subsequent judgement on relevance was based on the full 181 
article. Disagreements were resolved by discussion, with involvement of a third reviewer when 182 
necessary. Following the initial screening, full texts of identified studies were obtained and 183 
screened firstly by a single reviewer. In case of doubt, a second reviewer decided on the suitability 184 
of a paper. Where multiple publications of the same study were identified, data were extracted and 185 
reported as a single study. 186 
  187 
2.4 Evidence synthesis 188 
 189 
The details of each study’s design and methodology and the key characteristics of the data source 190 
were tabulated and discussed. We present a summary of the methods we found that can mitigate for 191 
confounding, or its synonyms as unmeasured, unobserved, hidden or residual. We note the 192 
historical frequency and context of the application of those methods, to comment on progress in 193 
causal inference and identify directions for future research. 194 
3 Results 195 
 196 
3.1 Included studies 197 
 198 
Our searches returned 734 unique titles and abstracts, with 275 papers retrieved for detailed 199 
consideration Of the 275 studies eligible for a full-text review, 154 were excluded (see flow 200 
diagram: Figure 1).  201 
 202 
A total of 121 studies were identified as performing a QE analysis on non-randomised longitudinal 203 
data on human subjects, identifiable at an individual level, and so included for a full review of the 204 
text (Appendix B). 205 
 206 
The QE methods identified in the review are summarised inTable 1. The most frequent method was 207 
instrumental variable analysis (IVA) found in 86 of the studies (Figure 2) – a method that uses an 208 
unconfounded proxy for the intervention or exposure. For successful adjustment, the proxy or 209 
instrument should be strongly, causally associated with the exposure or intervention, and the 210 
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instrument should only affect the outcome through the exposure. In addition to IVA, three of these 211 
also applied difference-in-differences (DiD) – a method that typically uses pre-exposure outcomes 212 
to adjust for unmeasured confounding and assumes any trends unrelated to the exposure are the 213 
same in both groups. Seven more studies derived estimates from a combination of both IVA and 214 
DiD, two of which assumed an absence of higher order autocorrelation to use lagged observations 215 
of the treatment variable as an instrument. Beside the 11 studies applying DiD either in conjunction 216 
with or in addition to IVA, we identified a further 21 studies, in which the sole QE method was 217 
recognised as a DiD approach. 218 
 219 
We found five studies applied the prior event rate ratio method, a before-and-after approach that 220 
can be aggregated to the treatment level for survival or rate outcomes and analogous to DiD. In all 221 
five cases the methods were applied to longitudinal, individual patient data. Similarly regression 222 
discontinuity (RD) was used for such data in three of the studies included for review. Another three 223 
focused on propensity score calibration (PSC). One study introduced perturbation testing and 224 
perturbation analysis, while another discussed the use of negative control outcomes.  225 
 226 
3.1.1 Studies excluded at full text 227 
 228 
The principal reason for exclusion in 94 of the studies, according to our eligibility criteria, was the 229 
absence of longitudinally observed, non-randomised outcomes on all individually identifiable 230 
persons, although other characteristics may also have justified their exclusion. No particular 231 
method was associated with the absence of longitudinal data on identifiable individuals with this 232 
studies in this exclusion category comprising 59% DiD and 28% instrumental variable analyses 233 
compared, respectively, to 53% and 32% of all 154 of the rejected studies. Having fewer than 1000 234 
longitudinally observed individuals excluded 23 studies, among which those using instrumental 235 
variable analysis (IVA) numbered 15. Seven were excluded for not employing a QE method for 236 
unmeasured confounding. Five studies presented exploratory analyses without a focused clinical 237 
question; five were either method reviews or commentaries without an application of methods to 238 
data; one study duplicated a dataset already marked for inclusion, while another failed to specify 239 
the instrumental variable used. Of particular note were the 18 studies using the DiD approach that 240 
were excluded because no explicit justification was made for using the method to address 241 
unmeasured confounding, or any of its synonyms. In these studies, justification of the method was 242 
centred more on econometric concerns over time trends, and presented in terms of controlling for 243 
those trends rather than pre-existing differences between the control and exposed group. 244 
 245 
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3.2 Results of the included studies 246 
 247 
So far studies have been categorised according to their identified QE method. However, certain 248 
properties are shared across some of the methods, and can be classified according to how they 249 
reconcile their specific assumptions with the information offered by the structure of big, 250 
longitudinal data that typifies EHRs. In particular, we organised our results around how each 251 
method had incorporated longitudinal information, and the assumptions required. The stable of 252 
before-and-after methods, that includes PERR and DiD, implicitly incorporates longitudinal 253 
information. Thereafter the challenge is how to relax the assumption of time-invariant confounding. 254 
Conversely, IVA is not uniquely applicable to longitudinal data, but we were able to broadly 255 
classify the types of instruments used (Table 2), some of which did utilise longitudinal information. 256 
We found out of the total 121 studies, 77 incorporated some element of longitudinal information 257 
into their analysis. 258 
 259 
3.2.1 Incorporation of external/additional data 260 
 261 
The propensity scores (PS), the predicted probability of exposure or treatment conditioned on 262 
measured confounders,were used in the seminal work on propensity score calibration (PSC) by 263 
Stürmer to calibrate an error-prone PS against a gold-standard PS and hence arrive at an inference 264 
for the level of unmeasured confounding bias 7. The two subsequent PSC papers examined the 265 
tenability of the method’s assumptions, firstly using simulated data to evaluate the conditions 266 
necessary to violate the surrogacy assumption 8. The second primarily used simulated data and 267 
applied the results to registry data to demonstrate a framework for determining size and direction of 268 
bias from one measured and one hidden confounder 9. 269 
 270 
3.2.2 High-dimensional data 271 
 272 
Since PSC collapses multiple, potential confounding variables down to the single dimension of a 273 
propensity score, the three PSC papers can also be considered a means of dealing with high-274 
dimensional data. In addition to these, our review also included a novel data-mining approach that 275 
proposed to exploit the many factors (perturbations) that may be weakly associated with the 276 
unmeasured confounders from a high dimension dataset 10, for which longitudinal data may 277 
mitigate for incorrect adjustment of a collider. Perturbation analysis was successfully demonstrated 278 
on simulated data, although accidental inclusion of a measured confounder required many more 279 
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perturbations to correct the resulting bias. Both the perturbation method and PSC were also 280 
proposed as sensitivity analyses. 281 
 282 
3.2.3 Quasi-experimental adjustment without longitudinal assumptions 283 
 284 
Those studies characterised as using a QE method without any longitudinal dimension were PSC 285 
and PT as described above. We also added to this category 11 examples of Mendelian IVA 11–21 286 
plus 32 other IVAs without historic or lagged instruments 22–53. While time-based instruments may 287 
at first seem longitudinal, these instruments, such as date of therapy, would need to be related to 288 
previous exposures or outcomes to be considered longitudinal. In some cases, survival times or rate 289 
data were used, but such outcomes do not intrinsically imply longitudinal adjustment for 290 
confounding. In spite of these “cross-sectional” approaches, all studies were based on some form of 291 
longitudinal data at the person level, as demanded by our inclusion criteria. Among the 43 non-292 
Mendelian IVA papers in this non-longitudinal category, one study adjusted for non-longitudinal 293 
fixed effects within twins 39. In another three, discussed below, the analysis was supplemented with 294 
DiD 38,47, and with IVA applied to first-differences54. 295 
 296 
One study examined the effect of lagged, cumulative exposure to radiation on lung cancer in 297 
uranium miners and nuclear workers 55. The problem of unmeasured confounding was addressed 298 
using a method developed in earlier work that proposed negative control outcomes and exposures 299 
as a means of both detecting and potentially resolving confounding bias56. Here the choice of death 300 
due to chronic obstructive pulmonary disorder as a negative control outcome was informed by 301 
clinical knowledge of there being no direct relationship with the exposure  except through the 302 
possible confounder, smoking. Given a plausible negative control outcome or exposure, the method 303 
offers at least a means of testing for confounding, and potentially a method of adjustment under the 304 
assumption that the association between the unmeasured confounder and the negative outcome is 305 
similar in magnitude to that between the same confounder and the outcome of interest. 306 
 307 
3.2.4 Quasi-experimental adjustment assuming time-invariant longitudinal information 308 
 309 
We found 36 IVA studies that used lagged information or history about the individuals’ exposure 310 
as instruments 54,57–92. One study had recourse to the random assignment from a previous study, and 311 
used this as an instrument 69. Except for that and four other different exceptions, the instruments 312 
were all based at least in part on the previous intervention, or history of interventions, of the 313 
clinician or healthcare facility. Characteristics of the clinician or facility may be chosen as 314 
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instruments as they are more likely to affect the treatment only. This avoids direct associations with 315 
the individual and their outcome, and so better enforces the exclusion restriction – the exclusion of 316 
the instrument’s association with the outcome except through the treatment under study. While no 317 
assumptions are made about the dependence of confounding on time, the strength of the instrument 318 
clearly rests on a significant association between previous treatment(s) and the current treatment 319 
under investigation. In this regard, if the strength of an instrument varies with time, this may 320 
undermine its utility. 321 
 322 
In total, 24 studies also incorporated longitudinal information through the stable of methods that, in 323 
an abuse of terminology, we collectively referred to as the DiD approach. These included the 18 324 
examples cited as using DiD regression 93–110 alone, and four fixed effects (FE) 111–114. Either 325 
through fixed effects at the individual level or through aggregate-level regression operationalizing 326 
the DiD approach, these methods “ignore” the effect of confounding, which is assumed to be time-327 
invariant. At the individual level, time invariant confounding can be ignored by assigning nuisance 328 
dummy variables for each individual, or cancelled out through demeaning the observations, or 329 
through the first differences of observations on each individual. Two of the studies also extended 330 
DiD to allow different exposure effects and trends across two-level sub-groups in the higher-order 331 
contrast of difference-in-difference-in-differences 95,106. Fourteen studies also adjusted for 332 
individual-level fixed effects either through direct inclusion of their covariates, or through 333 
matching or weighting on the propensity score of the covariates. This was perhaps a more rigorous 334 
and precise approach, accounting for known confounders, and yielding smaller standard errors for 335 
the estimated treatment effect. However, an assumption of time-invariant confounding was still 336 
required, with a null difference between exposure groups in the prior period being evidence of 337 
adjustment for time-invariant confounding only. Two of the 24 DiD studies also re-analysed their 338 
data using IVA 38,47, which provided an albeit limited opportunity to compare the relative 339 
performance of these methods. In the study by Schmittdiel et al.  of how statins delivered by mail 340 
order affects cholesterol control47, the intervention coefficient from modelling the single main 341 
outcome was larger through DiD analysis and its standard error smaller than those from IVA, large 342 
standard errors being a feature of weak instruments. The study by Lei and Lin investigated the 343 
effect of exposure to a new medical scheme on 15 health outcomes and rates of health-service 344 
utilisation38. The effects were either not significantly different from the null or were significant and 345 
of similar magnitude with similar standard error except for two outcomes, where the effect size was 346 
significantly larger for IVA. 347 
 348 
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Time-invariant confounding, also known as the parallel trends assumption, was relaxed by 349 
including dummy variables for the year and its interaction with the treatment dummy in a fixed-350 
effects analysis, which allowed the unobserved trend to vary between exposure groups 113 using 351 
methods developed in economics and therefore not captured by this review 115,116. The results from 352 
this DiD with differential trend model were presented alongside those from the simple pooled DiD 353 
model and DiD with individual fixed-effects for the effect of financial incentives in care services. 354 
Tests confirmed parallel trends could be assumed in three outcomes, but out of the five outcomes 355 
presented, four were statistically significant and in all, the estimated effect size by differential 356 
trends was greater. 357 
 358 
Our review also included six studies applying the prior event rate ratio method, a before-and-after 359 
analogue applicable to survival and rate data 117–122. The first two published were the seminal 360 
presentation of the method applied to registry data. Also included was a comprehensive evaluation 361 
by Uddin et al. of the performance of PERR under a wide array of simulated, theoretical settings, 362 
under which bias was shown to increase with a greater effect of the prior events on subsequent 363 
exposure or intervention.  When prior events strongly influence the likelihood of treatment, the 364 
exposure effect from the PERR method can be more biased than estimates from conventional 365 
methods121. The problem was re-examined in a recently published study, which provided a more 366 
general statistical framework for PERR adjustment and considered the potential for generalising the 367 
method to allow more flexible modelling122.  368 
 369 
3.2.5 Dynamic, longitudinal quasi-experimental methods and time-varying information 370 
 371 
While regression discontinuity (RD) could suggest a longitudinal design, this is not exclusively so, 372 
and two RD studies were excluded because of this (one applied to spatial data while the other data 373 
was not longitudinal). Of those included all three could be said to accommodate time varying 374 
trends 123–125, and two of these were nested within a pre-post design: Zuckerman et al. were explicit 375 
in their methodological study in identifying the robustness to time-varying confounding, in which 376 
inhaler use in asthmatic patients was served as both the outcome variable in the post-test period as 377 
well as the assignment variable in the pre-test period125. In the study of the effect school-leaving 378 
age on mortality by Albouy, different slopes were modelled for the assignment variable, year of 379 
birth, after the cut-off date123. This acknowledged different maturation rates after assignment. 380 
However, as long as the assumptions of the method were met, assignment should have been as 381 
good as randomised, and so no further assumptions about the temporality of confounding was 382 
required. 383 
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 384 
We also picked up six examples where IVA had been combined with either DiD or a fixed effects 385 
model, first appearing in our review with example from 2003 126. In Fortney’s 2005 study of 386 
treatment for depression 127, this combination method was justified as a control for time varying 387 
confounding, referred to as second-order endogeneity. Further examples of the fixed-effects 388 
instrumental variable model were found 128,129. The roles of lagged treatments and outcomes as 389 
possible IVs and predictors were extensively considered in O’Malley’s study of whether the 390 
introduction of more expensive medication could have led to improved cost-effectiveness in the 391 
long term54. The author cautioned that the exclusion restriction may be difficult to satisfy when 392 
using the lagged treatment as an IV after first differencing. However, two studies 130,131 used 393 
differences in the lagged explanatory variable as the IVs to adjust for second-order endogeneity in a 394 
first-differences analysis following methods, not captured by our review, but developed in the 395 
realm of Economics 132–134. Referred to as the dynamic panel model or IV-GMM, this method was 396 
implemented efficiently through generalised method of moments. In their report on healthcare 397 
expenditure in patients with rheumatoid arthritis, Kawatkar et al. found the yielded estimates were 398 
further from the null with larger standard errors when compared to those from FE alone130. 399 
 400 
3.3 Implementation of methods 401 
 402 
While choice of method in each study often rested on which extra information was available to 403 
address the issue of unmeasured confounding, method selection may also have been informed by 404 
the research area. The negative control method had its origins in epidemiology, with applications to 405 
occupational health policy. Likewise, the PERR method was developed exclusively on health data, 406 
with applications to drug safety and public health policy. Reflecting their origins in health 407 
econometrics, some studies were published in journals partially or entirely dedicated to the subject, 408 
with 15 published38,54,93–95,98,103,104,111–114,126,127,130 in this field out of the 32 studies using DiD and 409 
2923,24,28–30,32,33,36,41,46,48,49,51,52,66,69–72,77,81,84,86,135 out of the 86 using IVA. Under the inclusion 410 
criteria, all studies had health outcomes or interventions. Mendelian IVA necessarily includes 411 
genetic information, and all were published in health-related journals. In contrast, all three studies 412 
using RD were published in health econometric journals. 413 
 414 
Before implementing one of the proposed methods, a natural first step is for the researcher to try to 415 
assess how much bias from unmeasured confounding is likely to be present.  While many of the 416 
included studies reported raw or unadjusted descriptive estimates, bias estimation was limited 417 
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either to considering the contribution from known confounders, including those summarised as a 418 
propensity score, or to methods, such as perturbation testing/analysis and negative controls 419 
methods, in which bias evaluation is an incremental step in adjustment. Under the assumption of 420 
time-invariant confounding, the difference-in-differences method may potentially offer a way of 421 
evaluating bias by modelling group differences in the pre-exposure period. However, few studies 422 
evaluated hidden bias in this way47,96,112. The regression formulation of the DiD method effectively 423 
by-passes separate analysis of the prior period. Instead studies often discussed the within-group 424 
changes over time. Similarly, the prior-period estimate from the PERR method implicitly offers an 425 
evaluation of confounding bias under the same assumptions, yet none of the studies presented 426 
information on outcomes in the prior period in this way. A direct evaluation of unmeasured 427 
confounding is less straight-forward in IVA, with further diagnostic tests only recently developed 428 
for the association between instrument and confounders136,137 . 429 
 430 
4 Discussion 431 
 432 
This review examined the application of methods to detect and adjust for unmeasured confounding 433 
in observational studies, and was motivated by recent calls to utilise EHRs. Most of the reviewed 434 
studies used more established methods such as DiD and particularly IVA. We summarised how 435 
studies exploit the longitudinal information afforded by EHRs. 436 
 437 
It may be tempting to view electronic health records and medical insurance claims data as a 438 
problem of large observational data, and hence search for solutions through data mining. However, 439 
ethics governing patient data collection, plus limited clinician time is likely to preclude data with 440 
very large dimensions. For that reason, it is doubtful there would be enough dimensions for a 441 
method like Perturbation Analysis (PA) to be a practical solution. In addition, a greater number of 442 
variables would likely include enough information about the confounders to obviate the need for 443 
further adjustment through PA. More generally, the purpose of EHRs primarily as an administrative 444 
tool limits the scope for data mining of known confounders. Similarly, limited availability of gold-445 
standard datasets may have confined the use of external data, as in PSC, to but a few examples. 446 
 447 
We were surprised by the number of studies using IVA alone. While Mendelian randomisation has 448 
its advantages for many studies as a reasonable guarantor of the exclusion restriction, in general 449 
IVA typically suffers from the weak-instrument problem, resulting in large standard errors and 450 
wide confidence intervals. Longitudinal data offer an opportunity to reinforce the exclusion criteria 451 
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by choosing historical or lagged instruments. However in doing so, the causal structure needs to be 452 
understood to avoid opening up “back door” paths and inducing further bias54. DiD arguably offers 453 
advantages over IVA in being more intuitive and easier to conceptualise, and with the longitudinal 454 
data in EHRs it should be inherently easier to work with prior observations than to identify strong 455 
instruments. Even though before-and-after methods are not subject to the imprecision of weak 456 
instruments, the resulting estimates are only unbiased if the unobserved confounders exert a 457 
constant effect over the observation windows before and after exposure. Where multiple 458 
observations per individual exist, time may be paramaterised and different trends between exposure 459 
groups can be accommodated in DiD with differential trends, but a time invariant assumption about 460 
confounding must still be made. To partially or wholly relax this particular assumption, instrument 461 
variable analysis can be incorporated into the fixed effects model. Assuming the instrument’s 462 
exclusion restriction is satisfied then this doubly-robust approach affords the advantage of DiD 463 
over possibly weak instruments, while mitigating for some or all of the time-dependent 464 
confounders ignored by DiD alone. Similarly, where multiple previous treatments or exposures are 465 
recorded, the differenced lagged treatments can be utilised as IVs in a fixed effects model to 466 
accommodate time-dependent confounding bias using the generalized method of moments system, 467 
referred to as IV-GMM or the dynamic panel model. 468 
 469 
Another potentially robust approach to unmeasured confounding would the RD design, although 470 
the small number of examples in our review probably reflects the limited number of scenarios 471 
where this can be reasonably applied. Another concern over and above the usual technical 472 
challenges of applying the RD method is that in spite of heath records promising ample data, the 473 
sample would need to be reduced to an interval around the cut-off that ensures exchangeability of 474 
the two treatment groups. In this case generalisability would be restricted to individuals with 475 
characteristics found in the interval. As with RD, PERR was another method that was found in 476 
relatively few studies. This may have been in large part due to its recent development, rather than 477 
any technically demanding aspect of its application, since it simply extends the before-and-after 478 
approach of DiD to survival and rate data - outcomes that are common enough in health research.  479 
However, the PERR approach does require strong assumptions including time-invariant 480 
confounding and the absence of an effect of prior events on likelihood of future treatment122.   481 
 482 
Methods such as IVA and DiD have their origins in the sphere of econometrics, where randomised 483 
experiments are rare. We found that in importing DiD, some of the studies failed to explicitly 484 
acknowledge the problem of confounding bias. Instead justification for the method was presented 485 
in terms of the common trends assumption. Discussion of possible confounding bias is regarded as 486 
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essential by most QA toolkits for observational data, and it is important that health researchers 487 
explicitly recognise this threat to the internal validity of non-randomised studies. Conceptually a 488 
non-temporal analogue of DiD would be the NCO method, which itself was presented foremost as 489 
a method for detecting unmeasured confounding. Given doubts over satisfying necessary 490 
assumptions for their implementation, authors of this method along with propensity score 491 
calibration and perturbation analysis have suggested that, as sensitivity analyses, these can at least 492 
offer an insightful complement to QE adjustment.  493 
 494 
Choosing between methods to reduce unmeasured confounding bias is challenging and we found 495 
few studies that directly compare methods. The performance of different methods will depend on 496 
factors such as the nature of the underlying confounding, the type of exposure and outcome, and 497 
the sample size138  The type of data available will also guide the choice of method.  For example, 498 
the instrumental variable method requires a suitable instrument and DiD / PERR require data on at 499 
least two periods. In practice, no one method is likely to be best suited to all problems, and it is 500 
essential for investigators to carefully assess the potential biases in each proposed study, where 501 
possible tailoring the methods or combination of methods to address these biases139.  Our review 502 
has highlighted how use of longitudinal information is one additional and potentially important 503 
consideration in this process.    504 
 505 
While our review focussed on the problem of adjustment using analytic methods, many problems 506 
associated with observational data may be pre-empted by use of an appropriate study design140.  507 
Before choosing an appropriate analytic method, it is recommended that investigators carefully 508 
identify and match individuals for the control and intervention groups in order not to exacerbate 509 
any bias3. The importance of study design is often discussed with a view to minimising 510 
confounding bias from unmeasured sources, with the subsequent adjustment accounting for 511 
observed confounders only141, usually through the matching, weighting or adjustment of propensity 512 
scores142. Where the success of the design remains in doubt, or its criteria cannot be fully met, then 513 
investigators will inevitably need recourse to some of the alternative methods reviewed in this 514 
report.  515 
 516 
The reviewed studies did not seek to distinguish between the different mechanisms of bias. 517 
Confounding by indication, deemed intractable by many researchers using the observed data143,  518 
was seen to create additional sources of bias in two separate simulation studies applying the 519 
“longitudinal” method of PERR, when an association was modelled between prior events and 520 
treatment status in the study period121,122. Another common form of selection bias in 521 
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pharmacoepidemiologic studies is the healthy user bias and this works in the opposite direction to 522 
confounding by indication, distorting treatment-outcome associations towards the treatment 523 
looking beneficial3.  Further research is needed to understand how each of the methods in this 524 
review is affected by the different types of confounding. 525 
 526 
An inherent limitation of this large, wide-ranging review is that it precluded meaningful data 527 
synthesis due to the mix of different data and study types.  Furthermore, we could only find a few 528 
examples where the performance of different methods was compared within the same study. We 529 
also stipulated in the inclusion criteria that unmeasured confounding, or any of its synonyms, 530 
should be given as justification for methods in its adjustment. This may have inadvertently 531 
excluded some papers, where justification was implicit, but good practice in health research 532 
demands acknowledgement of this source of bias where applicable. While our search terms were 533 
specific to the scope of our review, we accept that this may have inadvertently excluded relevant 534 
methods and studies. Some methods, such as negative control outcomes, that were identified in the 535 
original search were not included as explicit terms in the search strategy, and further secondary 536 
searches may have uncovered additional studies using these methods. We also acknowledge that 537 
there may be other relevant methods for addressing unmeasured confounding that have been missed 538 
by the search strategy. Consequently, we made inferences about the relative application of methods 539 
with caution. However, we were surprised so many studies focussed solely on IVA as the sole 540 
means of adjustment. A similar conclusion was echoed by a different review on regression 541 
discontinuity designs that found interest was growing in RD only as recently as 2014 144. 542 
 543 
By choosing to focus on methods with an independent control arm for each treatment, our review 544 
excluded case only designs including case-crossover designs (CCO) and the self-controlled case-545 
series design.  This class of methods addresses unmeasured confounding by making comparisons 546 
within individuals so that each individual acts as his or her own control.  Another case-only design, 547 
the case-time control design, is an extension of the CCO design that uses information from a 548 
historical control group in a similar way to the PERR method.  These approaches are reviewed by 549 
Uddin et al138 and Nordmann et al145. 550 
 551 
This review has considered a range of promising new methods for addressing unmeasured 552 
confounding in non-randomised studies. However, consistent with prior research on dissemination 553 
and uptake of statistical innovations146, the rate of knowledge translation has been slow and we 554 
found that most studies in our review used established methods such as IVA and DiD.  A recent 555 
study by Cadarette et al has shown how Rogers’ Diffusion of Innovations model can be used to 556 
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describe the adoption of novel methodologies in pharmacoepidemiology147 and this provides a 557 
useful resource for interpreting the uptake of methods in this review.  Cadarette et al proposed five 558 
principles for authors of methodological innovations that may improve translation into practice 147: 559 
(1) clearly describing the methods using foundational principles; (2) comparing results to 560 
established methods; (3) providing sample data, code or calculation examples; (4) early 561 
communication, support and testing; and (5) providing methodological and reporting guidance. 562 
These recommendations offer a useful checklist for researchers developing methods for addressing 563 
unmeasured confounding in observational studies. Of particular relevance in the context of this 564 
review is the need for more extensive evaluation and comparison of the emerging methods in a 565 
range of settings.   The review also addresses the need for methodological guidance through 566 
highlighting the potentially important role of longitudinal information in addressing confounding 567 
bias and has identified this as an area for further development. 568 
5 Conclusions 569 
 570 
Our review showed how seminal work in econometrics has influenced practice in dealing with 571 
unmeasured confounding in clinical and epidemiological research. Although the issue of 572 
unmeasured confounding is widely acknowledged, we found that longitudinal information in 573 
observational studies appears under-utilised. Lagged and historical characteristics associated with 574 
the treatment may help enforce the exclusion restrictions of instrumental variables under the 575 
appropriate causal structures, while before-and-after methods, such as DiD and PERR, afford an 576 
intuitive approach without the imprecision of weak instruments. Furthermore, they offer a direct 577 
evaluation of time-invariant confounding bias. The most robust methods we found applied 578 
instrumental variable analysis to the fixed effects difference-in-differences method, where such 579 
suitable instruments or difference lagged variables could be assumed to satisfy the exclusion 580 
restriction.  While there are sometimes good technical reasons for choosing one mode of analysis 581 
over another, many questions remain over the most appropriate methods.  All methods rely on 582 
assumptions, but little guidance is available to applied researchers as to the empirical settings in 583 
which particular methods can be safely used.  Few studies directly compare different methods and 584 
more research is needed to the establish the relative performance of the methods in realistic 585 
settings.   586 
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Figure 2: Plot of frequency of reviewed methods for mitigating for unmeasured confounding by: difference-in-differences [black]; Instrumental variable analysis (IVA) [mid-grey]; 
Other [light grey] includes regression discontinuity, prior event rate ratio method, propensity score calibration, perturbation analysis, negative control outcomes, fixed effects with 
IVA and dynamic panel models. Note: the low frequencies in 2015 was attributable to the May cut-off for inclusion in that year.
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Method Description Obstacles to implementation 
Frequency 
of methods 
Instrumental variable 
analysis (IVA) 
Upon identification of a suitably strong instrument, the influence of bias may be reduced 
through post-hoc randomisation. The instrumental variable should be highly determinant of 
the intervention or treatment received, while satisfying the exclusion assumption of being 
independent of the outcome other than through the treatment (Wright 1928; Angrist 1991). 
In practice, finding an instrument with a sufficiently strong treatment association is a stumbling 
block in many analyses (Bound, Jaeger, and Baker 1995; Baser 2009). Association of the instrument 
with the outcome exclusively through the treatment is an untestable assumption, particularly if an 
indirect association exists through an unmeasured covariate. 
79 
Difference-in-
differences (DiD) 
A biased effect estimate between two treatment groups may be corrected by the same 
estimates from a treatment-free period prior to the exposure, which should be a measure of 
the confounding bias contributed to the treatment effect (Ashenfelter and Card 1984). 
Aggregated at the treatment group level, this is operationalised in regression as a period-
treatment interaction. At an individual level, demeaning, first-differencing or dummy 
variables for each individual may yield bias-free fixed effects, contingent on assumptions. 
The method is contingent on the availability of repeated outcomes in both periods and  invokes a 
time-invariant confounding assumption: that the confounding bias as captured by the estimated 
treatment effect in a treatment-free period prior to exposure is constant through to the study 
period. 
24 
Prior event rate ratio 
(PERR) 
Analogous to the DiD method for time-to-event or rate data, a biased estimate of the hazard 
ratio or the incidence rate ratio is adjusted through its ratio with that from a treatment-free 
prior period (Tannen et al. 2008). 
As with the assumption for DiD, repeatable outcomes and a constancy of the unmeasured 
confounding bias is required across both periods, before and after the exposure.  Prior event 
occurrence should not influence the likelihood of future treatment. 
5 
Fixed effects 
instrumental variable 
analysis (FE IVA) 
IVA may be applied to DiD estimation to mitigate for second-order endogeneity: the time-
varying part of the bias that may not have been adjusted for by DiD. 
Assumptions of IVA apply 5 
Dynamic panel model, 
or Instrumental variable 
- generalised method of 
moments (IV-GMM) 
Lagged observations of the confounded (endogenous) explanatory variable are introduced in 
a first-differences fixed effects analysis so that the differences of the lags become the 
instrumental variables in a generalised method of moments estimation. 
Assumptions of IVA apply. Here the differenced lags should not be correlated with the differences 
in the error terms. 
2 
Regression 
discontinuity (RD) 
RD is a design for analysis based on a treatment assignment determined by a cut-off applied 
to a continuous variable that is preferably measured with some random noise (as many 
clinical tests may be). The outcome can then be modelled on treatment for individuals within 
a certain interval from the cut-off of the assignment variable to ensure exchangeability 
between individuals for robust causal inference (Thistlethwaite and Campbell 1960) 
Where assignment is not sharply determined by the cut-off, an increase in the probability of 
treatment may be observed leading to a "fuzzy" version of RD. Continuity in the assignment 
variable is assumed, otherwise manipulation of assignment and reverse causality may be 
suspected. Assignment should be locally random around the cut-off and makes the weak 
assumption that no unobserved covariates are  discontinuous around the assignment cut-off. 
3 
Propensity score 
calibration (PSC) 
PSC adjusts for residual confounding in the error-prone main dataset by importing 
information about the unmeasured confounders from a smaller, external “gold-standard” 
dataset (Stürmer et al. 2005). Analysis in the main dataset is adjusted using a single 
dimension propensity score of the measured corrected for unmeasured confounding by 
regression calibration against the gold-standard propensity score. 
Successful adjustment is wholly dependent on the availability of another dataset containing the 
exposure variable and error-free predictor,  with individuals that are relevant enough to those in 
the main dataset and under similar enough conditions to assure sufficient overlap between the 
two datasets. 
3 
Perturbation 
testing/analysis (PT/PA) 
This data mining approach aims to mitigate for unmeasured confounding by adjusting for 
many measured variables that are weakly associated with the unobserved confounding 
variables (Lee 2014). Simulation in the single reviewed example demonstrated this may 
require 100's, if not 1000's of perturbation variables (PV). 
This requires a very highly dimensional dataset, which may ultimately obviate the need for indirect 
adjustment if the most or all of the confounders are captured. Simulation demonstrated the bias 
may be exaggerated if a confounder is inadvertently identified as a PV, requiring many more true 
PVs to correct the bias. The number of PVs may exceed the available degrees of freedom 
necessitating clustering. 
1 
Negative control 
outcome / exposure 
(NCO/NCE) 
A negative controlis causally related to measured and unmeasured confounders affecting the 
exposure and main outcome, but not directly causally related to exposure and outcome 
themselves. As such, the negative control may be used to detect confounding bias in the 
main study, and potentially to indirectly adjust for this (Richardson et al. 2014) 
This assumes that the effect of the unmeasured confounders on the main outcome is similar to 
that affecting the negative control. 
1 
Table 1: Summary of methods to mitigate against unmeasured confounding captured by systematic review, and the frequency of their use amongst the captured papers 
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IV type Explanation/ Example No. of papers 
Total 
frequency 
Mendelian 
Genetic characteristics :Single 
nucleotide polymorphisms 
11 11 
Geographic 
Differential distance between 
patient's postcode and nearest 
health facility 
19 
1 
 
1 
20 
Time 
Time-based characteristic of 
treatment such as date of therapy 
6 
2 
10 
Historical 
Usually prescribing preference of 
physician or facility based on 
historical records of previously 
administered therapies 
31   34 
Lagged 
Previous therapy or outcome of 
patient 
6 6 
Randomisation Original randomisation 1 1 
Other 
Characteristics of individual 
e.g: age of patient, weight of 
offspring 
8 8 
Table 2: Frequency of instruments categorised by type used in instrumental variable analyses 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 28
Appendix A 
 
SULRUHYHQWDQGUDWLRWLDE

SDLUHGFR[PRGHOWLDE

RU

LQVWUXPHQWDOYDULDEOHVWLDE

LQVWUXPHQWDOYDULDEOHDQDO\VLV

SURSHQVLW\VFRUHFDOLEUDWLRQWLDE

UHJUHVVLRQGLVFRQWLQXLW\GHVLJQWLDE

GLIIHUHQFHLQGLIIHUHQFHVWLDE

GLIIHUHQFHDGMGLIIHUHQFHVWLDE

UDWLRRIUDWLRVWLDE

UDWLRDGMUDWLRVWLDE

LQWHUUXSWHGWLPHVHULHVWLDE

VHJPHQWHGUHJUHVVLRQWLDE

VHQVLWLYLW\DQDO\VLVRUVHQVLWLYLW\DQDO\VLVWLDEDQGXQPHDVXUHGRUUHVLGXDORUKLGGHQDQG
FRQIRXQGLQJRUFRQIRXQGHUWLDE

RU

XQPHDVXUHGRUUHVLGXDORUKLGGHQRUXQREVHUYHGRURPLWWHGDQGFRQIRXQGLQJRU
FRQIRXQGHUWLDE

FRQIRXQGLQJYDULDEOH
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
FRYDULDWHVWLDE

ELDVWLDE

VHOHFWLRQELDV

RURURURU

REVHUYDWLRQDOVWXG\

REVHUYDWLRQDGMVWXGRUGDWDWLDE

EHIRUHDGMDIWHUDQGVWXG\RUVWXGLHVWLDE

QRQUDQGRPL"HGRUQRQUDQGRPL"HGWLDE

FDVHFURVVRYHUWLDE

FDVHFRQWUROWLDE

FDVHFRQWUROVWXG\

FRKRUWVWXG\WLDE

TXDVLH[SHULPHQWRUTXDVLH[SHULPHQWWLDE

TXDVLH[SHULPHQWDOVWXG\

FURVVVHFWLRQDOVWXG\WLDE

FURVVVHFWLRQDOVWXG\

VLPXODWLRQWLDE

FDVHWLPHFRQWUROWLDE
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EHIRUHDQGDIWHUDQGVWXG\RUVWXGLHVWLDE

RU

DQGDQG

RU

DQGDQG

RU

RU

DQG
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Appendix B 
 
Table 3: Table of included studies denoting QE method used and type of instrument, if applicable, where: IVA = instrumental variable analysis; RD = regression discontinuity; DiD = 
difference-in-differences; DiDiD = difference-in-difference-in-differences; PSC = propensity score calibration; PERR = prior event rate ratio 
Author Title Year QE method If IVA, IV type 
Bryson, W. C.; McConnell, J.; 
Krothuis, T.; McCarty, D. 
Extended-release naltrexone for alcohol 
dependence: persistence and healthcare 
costs and utilization 
2011 DiD  
Cheng, L.; Liu, H.; Zhang, Y.; Shen, 
K.; Zeng, Y. 
The impact of health insurance on health 
outcomes and spending of the elderly: 
Evidence from china's new cooperative 
medical scheme 
2015 DiD  
Gebel, M.; Vosemer, J. The impact of employment transitions on 
health in Germany. A difference-in-
differences propensity score matching 
approach 
2014 DiD  
Goetzel, R. Z.; Roemer, E. C.; Pei, X.; 
Short, M. E.; Tabrizi, M. J.; Wilson, M. 
G.; Dejoy, D. M.; Craun, B. A.; Tully, K. 
J.; White, J. M.; Baase, C. M. 
Second-year results of an obesity 
prevention program at the dow chemical 
company 
2010 DiD  
Higgins, S.; Chawla, R.; Colombo, 
C.; Snyder, R.; Nigam, S. 
Medical homes and cost and utilization 
among high-risk patients 
2014 DiD  
Kausto, J.; Viikari-Juntura, E.; 
Virta, L. J.; Gould, R.; Koskinen, A.; 
Solovieva, S. 
Effectiveness of new legislation on partial 
sickness benefit on work participation: a 
quasi-experiment in Finland 
2014 DiD  
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Kelly, Y.; Kelly, J.; Sacker, A. Changes in bedtime schedules and 
behavioral difficulties in 7 year old 
children 
2013 DiD  
Lin, W. C.; Chien, H. L.; Willis, G.; 
O'Connell, E.; Rennie, K. S.; Bottella, 
H. M.; Ferris, T. G. 
The effect of a telephone-based health 
coaching disease management program 
on medicaid members with chronic 
conditions 
2012 DiD  
Lyon, S. M.; Wunsch, H.; Asch, D. A.; 
Carr, B. G.; Kahn, J. M.; Cooke, C. R. 
Use of intensive care services and 
associated hospital mortality after 
massachusetts healthcare reform 
2014 DiD  
Menon, J.; Paulet, M.; Thomas, Iii J. Wellness coaching and health-related 
quality of life: A case-control difference-
in-differences analysis 
2012 DiD  
Moran, J. R.; Short, P. F.; Hollenbeak, 
C. S. 
Long-term employment effects of 
surviving cancer 
2011 DiD  
Osborne, N. H.; Nicholas, L. H.; Ryan, 
A. M.; Thumma, J. R.; Dimick, J. B. 
Association of hospital participation in a 
quality reporting program with surgical 
outcomes and expenditures for medicare 
beneficiaries 
2015 DiD  
Reid, R. O.; Ashwood, J. S.; Friedberg, 
M. W.; Weber, E. S.; Setodji, C. M.; 
Mehrotra, A. 
Retail clinic visits and receipt of primary 
care 
2013 DiD  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 33
Sadhu, A. R.; Ang, A. C.; Ingram-
Drake, L. A.; Martinez, D. S.; 
Hsueh, W. A.; Ettner, S. L. 
Economic benefits of intensive insulin 
therapy in critically Ill patients: The 
targeted insulin therapy to improve 
hospital outcomes (TRIUMPH) project 
2008 DiD  
Sarkar, U.; Lyles, C. R.; Parker, M. M.; 
Allen, J.; Nguyen, R.; Moffet, H. H.; 
Schillinger, D.; Karter, A. J. 
Use of the refill function through an online 
patient portal is associated with improved 
adherence to statins in an integrated 
health system 
2014 DiD  
Watt, C.; Abuya, T.; Warren, C. E.; 
Obare, F.; Kanya, L.; Bellows, B. 
Can reproductive health voucher 
programs improve quality of postnatal 
care? A quasi-experimental evaluation of 
Kenya ' s Safe Motherhood voucher 
scheme 
2015 DiD  
De Preux, L. B. Anticipatory ex ante moral hazard and the 
effect of medicare on prevention 
2011 DiD; DiDiD  
Rajaram, R.; Chung, J. W.; Jones, A. T.; 
Cohen, M. E.; Dahlke, A. R.; Ko, C. Y.; 
Tarpley, J. L.; Lewis, F. R.; Hoyt, D. B.; 
Bilimoria, K. Y. 
Association of the 2011 ACGME resident 
duty hour reform with general surgery 
patient outcomes and with resident 
examination performance 
2014 DiD; DiDiD  
Domino, M. E.; Norton, E. C.; 
Morrissey, J. P.; Thakur, N. 
Cost shifting to jails after a change to 
managed mental health care 
2004 DiD; Fixed effects  
Hodgkin, D.; Parks Thomas, C.; 
Simoni-Wastila, L.; Ritter, G. A.; Lee, 
S. 
The effect of a three-tier formulary on 
antidepressant utilization and 
expenditures 
2008 Fixed effects  
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Li, J.; Hurley, J.; DeCicca, P.; 
Buckley, G. 
Physician response to pay-for-
performance: evidence from a natural 
experiment 
2014 DiD pooled OLS; DiD 
(Fixed effects); DiD + 
differential trends 
 
Yoon, J.; Bernell, S. L. The role of adverse physical health events 
on the utilization of mental health services 
2013 DiD & Fixed Effects  
Fortney, J. C.; Steffick, D. E.; Burgess 
Jr, J. F.; Maciejewski, M. L.; Petersen, 
L. A. 
Are primary care services a substitute or 
complement for specialty and inpatient 
services? 
2005 IVA applied to DiD Geographic 
Hay, J.; Jhaveri, M.; Tangirala, M.; 
Kaliner, M. 
Cost and resource utilization comparisons 
of second-generation antihistamines vs. 
montelukast for allergic rhinitis treatment 
2009 IVA applied to Fixed 
effects 
Historical 
Chung, S.; Domino, M. E.; Stearns, S. 
C. 
The effect of retirement on weight 2009 Fixed Effects; IVA 
applied to Fixed effects 
Lagged 
Wagner, T. H.; Jimison, H. B. Computerized health information and the 
demand for medical care 
2003 IVA applied to Fixed 
effects 
Other 
Kawatkar, A. A.; Hay, J. W.; Stohl, W.; 
Nichol, M. B. 
Incremental expenditure of biologic 
disease modifying antirheumatic 
treatment using instrumental variables in 
panel data 
2013 Dynamic panel model 
(IV-GMM) 
Lagged 
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Piernas, C.; Ng, S. W.; Mendez, M. A.; 
Gordon-Larsen, P.; Popkin, B. M. 
A dynamic panel model of the associations 
of sweetened beverage purchases with 
dietary quality and food-purchasing 
patterns 
2015 Dynamic panel model 
(IV-GMM) 
Lagged 
Lei, X.; Lin, W. The new cooperative medical scheme in 
rural China: Does more coverage mean 
more service and better health? 
2009 Fixed effects; IVA; DiD Geographic 
Lin, M. J.; Liu, J. T. Do lower birth weight babies have lower 
grades? Twin fixed effect and 
instrumental variable method evidence 
from Taiwan 
2009 Fixed effects; IVA Geographic 
Schmittdiel, J. A.; Karter, A. J.; 
Dyer, W.; Parker, M.; Uratsu, C.; 
Chan, J.; Duru, O. K. 
The comparative effectiveness of mail 
order pharmacy use vs. local pharmacy 
use on LDL-C control in new statin users 
2011 DiD; IVA Other 
Basu, A. Estimating Decision-Relevant 
Comparative Effects Using Instrumental 
Variables 
2011 IVA Geographic 
Beck, C. A.; Penrod, J.; Gyorkos, T. 
W.; Shapiro, S.; Pilote, L. 
Does Aggressive Care Following Acute 
Myocardial Infarction Reduce Mortality? 
Analysis with Instrumental Variables to 
Compare Effectiveness in Canadian and 
United States Patient Populations 
2003 IVA Geographic 
Chen, L. F.; Chen, H. P.; Huang, Y. S.; 
Huang, K. Y.; Chou, P.; Lee, C. C. 
Pneumococcal Pneumonia and the Risk of 
Stroke: A Population-Based Follow-Up 
Study 
2012 IVA Geographic 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 36
Edwards, S. T.; Prentice, J. C.; Simon, 
S. R.; Pizer, S. D. 
Home-Based Primary Care and the risk of 
ambulatory care-sensitive condition 
hospitalization among older veterans with 
diabetes mellitus 
2014 IVA Geographic 
Frances, C. D.; Shlipak, M. G.; 
Noguchi, H.; Heidenreich, P. A.; 
McClellan, M. 
Does physician specialty affect the 
survival of elderly patients with 
myocardial infarction? 
2000 IVA Geographic 
Goldman, D. P.; Bao, Y. Effective HIV treatment and the 
employment of HIV+ adults 
2004 IVA Geographic 
Gowrisankaran, G.; Town, R. J. Estimating the quality of care in hospitals 
using instrumental variables 
1999 IVA Geographic 
Hirth, R. A.; Grabowski, D. C.; Feng, 
Z.; Rahman, M.; Mor, V. 
Effect of nursing home ownership on 
hospitalization of long-stay residents: An 
instrumental variables approach 
2014 IVA Geographic 
Kahn, J. M.; Werner, R. M.; David, 
G.; Ten Have, T. R.; Benson, N. M.; 
Asch, D. A. 
Effectiveness of long-term acute care 
hospitalization in elderly patients with 
chronic critical illness 
2013 IVA Geographic 
Linden, A.; Adams, J. L. Evaluating disease management 
programme effectiveness: An introduction 
to instrumental variables 
2006 IVA Geographic 
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Norton, E. C.; Lindrooth, R. C.; 
Ennett, S. T. 
Controlling for the endogeneity of peer 
substance use on adolescent alcohol and 
tobacco use 
1998 IVA Geographic 
Pilote, L.; Beck, C. A.; Eisenberg, M. J.; 
Humphries, K.; Joseph, L.; Penrod, J. 
R.; Tu, J. V. 
Comparing invasive and noninvasive 
management strategies for acute 
myocardial infarction using 
administrative databases 
2008 IVA Geographic 
Pracht, E. E.; Tepas, Iii J. J.; Celso, B. 
G.; Langland-Orban, B.; Flint, L. 
Survival advantage associated with 
treatment of injury at designated trauma 
centers: A bivariate probit model with 
instrumental variables 
2007 IVA Geographic 
Slade, E. P.; McCarthy, J. F.; 
Valenstein, M.; Visnic, S.; Dixon, L. B. 
Cost savings from assertive community 
treatment services in an era of declining 
psychiatric inpatient use 
2013 IVA Geographic 
Tsai, A. C.; Votruba, M.; Bridges, J. F. 
P.; Cebul, R. D. 
Overcoming bias in estimating the 
volume-outcome relationship 
2006 IVA Geographic 
Wehby, G. L.; Ullrich, F.; Xie, Y. Very low birth weight hospital volume 
and mortality: An instrumental variables 
approach 
2012 IVA Geographic 
Hadley, J.; Polsky, D.; Mandelblatt, J. 
S.; Mitchell, J. M.; Weeks, J. C.; Wang, 
Q.; Hwang, Y. T. 
An exploratory instrumental variable 
analysis of the outcomes of localized 
breast cancer treatments in a medicare 
population 
2003 IVA Geographic + 
Historical + 
Time 
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O'Malley, A. J.; Frank, R. G.; 
Normand, S. L. T. 
Estimating cost-offsets of new 
medications: Use of new antipsychotics 
and mental health costs for schizophrenia 
2011 IVA Geographic + 
Time 
Abrahamowicz, M.; Beauchamp, M. 
E.; Ionescu-Ittu, R.; Delaney, J. A. C.; 
Pilote, L. 
Reducing the variance of the prescribing 
preference-based instrumental variable 
estimates of the treatment effect 
2011 IVA Historical 
An, J.; Nichol, M. B. Multiple medication adherence and its 
effect on clinical outcomes among patients 
with comorbid type 2 diabetes and 
hypertension 
2013 IVA Historical 
Bekelman, J. E.; Mitra, N.; Handorf, E. 
A.; Uzzo, R. G.; Hahn, S. A.; Polsky, D.; 
Armstrong, K. 
Effectiveness of androgen-deprivation 
therapy and radiotherapy for older men 
with locally advanced prostate cancer 
2015 IVA Historical 
Bhowmik, D.; Aparasu, R. R.; Rajan, 
S. S.; Sherer, J. T.; Ochoa-Perez, M.; 
Chen, H. 
Risk of manic switch associated with 
antidepressant therapy in pediatric 
bipolar depression 
2014 IVA Historical 
Brooks, J. M.; Tang, Y.; Chapman, C. 
G.; Cook, E. A.; Chrischilles, E. A. 
What is the effect of area size when using 
local area practice style as an instrument? 
2013 IVA Historical 
Chuang, C. M.; Chou, Y. J.; Yen, M. S.; 
Chao, K. C.; Twu, N. F.; Wu, H. H.; 
Wen, K. C.; Chen, Y. J.; Wang, P. H.; 
Lai, C. R.; Chou, P. 
The role of secondary cytoreductive 
surgery in patients with recurrent 
epithelial ovarian, tubal, and peritoneal 
cancers: A comparative effectiveness 
analysis 
2012 IVA Historical 
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De Ridder, A.; De Graeve, D. Can we account for selection bias? A 
comparison between bare metal and drug-
eluting stents 
2011 IVA Historical 
Fang, G.; Brooks, J. M.; Chrischilles, 
E. A. 
Comparison of instrumental variable 
analysis using a new instrument with risk 
adjustment methods to reduce 
confounding by indication 
2012 IVA Historical 
Figueroa, R.; Harman, J.; Engberg, J. Use of Claims Data to Examine the Impact 
of Length of Inpatient Psychiatric Stay on 
Readmission Rate 
2004 IVA Historical 
Huesch, M. D. External adjustment sensitivity analysis 
for unmeasured confounding: An 
application to coronary stent outcomes, 
Pennsylvania 2004-2008 
2013 IVA Historical 
Huybrechts, K. F.; Brookhart, M. A.; 
Rothman, K. J.; Silliman, R. A.; 
Gerhard, T.; Crystal, S.; Schneeweiss, 
S. 
Comparison of different approaches to 
confounding adjustment in a study on the 
association of antipsychotic medication 
with mortality in older nursing home 
patients 
2011 IVA Historical 
Ionescu-Ittu, R. Treatment effect estimates varied 
depending on the definition of the 
provider prescribing preference-based 
instrumental variables 
2012 IVA Historical 
Kivimaki, M.; Vahtera, J.; Kawachi, 
I.; Ferrie, J. E.; Oksanen, T.; 
Joensuu, M.; Pentti, J.; Salo, P.; 
Elovainio, M.; Virtanen, M. 
Psychosocial work environment as a risk 
factor for absence with a psychiatric 
diagnosis: An instrumental-variables 
analysis 
2010 IVA Historical 
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Kramer, A.; Jager, K. J.; Fogarty, D. G.; 
Ravani, P.; Finne, P.; Perez-Panades, 
J.; Prutz, K. G.; Arias, M.; Heaf, J. G.; 
Wanner, C.; Stel, V. S. 
Association between pre-transplant 
dialysis modality and patient and graft 
survival after kidney transplantation 
2012 IVA Historical 
Kuo, Y. F.; Montie, J. E.; Shahinian, 
V. B. 
Reducing bias in the assessment of 
treatment effectiveness: Androgen 
deprivation therapy for prostate cancer 
2012 IVA Historical 
Lakdawalla, D. N.; Mascarenhas, 
M.; Jena, A. B.; Vanderpuye-Orgle, 
J.; Lavallee, C.; Linthicum, M. T.; 
Snider, J. T. 
Impact of oral nutrition supplements on 
hospital outcomes in pediatric patients 
2014 IVA Historical 
MacKenzie, T. A.; Tosteson, T. D.; 
Morden, N. E.; Stukel, T. A.; O'Malley, 
A. J. 
Using instrumental variables to estimate a 
Cox's proportional hazards regression 
subject to additive confounding 
2014 IVA Historical 
Margolis, D. J.; Gupta, J.; Hoffstad, O.; 
Papdopoulos, M.; Glick, H. A.; Thom, 
S. R.; Mitra, N. 
Lack of effectiveness of hyperbaric oxygen 
therapy for the treatment of diabetic foot 
ulcer and the prevention of amputation a 
cohort study 
2013 IVA Historical 
Parmar, A. D.; Sheffield, K. M.; Han, Y.; 
Vargas, G. M.; Guturu, P.; Kuo, Y. F.; 
Goodwin, J. S.; Riall, T. S. 
Evaluating comparative effectiveness with 
observational data: Endoscopic 
ultrasound and survival in pancreatic 
cancer 
2013 IVA Historical 
Pisoni, R. L.; Arrington, C. J.; Albert, J. 
M.; Ethier, J.; Kimata, N.; Krishnan, 
M.; Rayner, H. C.; Saito, A.; Sands, J. 
J.; Saran, R.; Gillespie, B.; Wolfe, R. A.; 
Port, F. K. 
Facility Hemodialysis Vascular Access Use 
and Mortality in Countries Participating in 
DOPPS: An Instrumental Variable Analysis 
2009 IVA Historical 
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Prentice, J. C.; Conlin, P. R.; Gellad, 
W. F.; Edelman, D.; Lee, T. A.; 
Pizer, S. D. 
Capitalizing on prescribing pattern 
variation to compare medications for type 
2 diabetes 
2014 IVA Historical 
Rassen, J. A.; Brookhart, M. A.; 
Glynn, R. J.; Mittleman, M. A.; 
Schneeweiss, S. 
Instrumental variables II: instrumental 
variable application-in 25 variations, the 
physician prescribing preference 
generally was strong and reduced 
covariate imbalance 
2009 IVA Historical 
Rosenthal, M. B.; Li, Z.; Robertson, A. 
D.; Milstein, A. 
Impact of financial incentives for prenatal 
care on birth outcomes and spending 
2009 IVA Historical 
Sheffield, K. M.; Riall, T. S.; Han, Y.; 
Kuo, Y. F.; Townsend, C. M., Jr.; 
Goodwin, J. S. 
Association between cholecystectomy 
with vs without intraoperative 
cholangiography and risk of common duct 
injury 
2013 IVA Historical 
Steingrub, J. S.; Lagu, T.; Rothberg, 
M. B.; Nathanson, B. H.; 
Raghunathan, K.; Lindenauer, P. K. 
Treatment with neuromuscular blocking 
agents and the risk of in-hospital 
mortality among mechanically ventilated 
patients with severe sepsis 
2014 IVA Historical 
Stukel, Thérèse A; Fisher, Elliott S; 
Wennberg, David E; Alter, David A; 
Gottlieb, Daniel J; Vermeulen, 
Marian J 
Analysis of observational studies in the 
presence of treatment selection bias: 
effects of invasive cardiac management on 
AMI survival using propensity score and 
instrumental variable methods. 
2007 IVA Historical 
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Tagami, T.; Matsui, H.; Horiguchi, H.; 
Fushimi, K.; Yasunaga, H. 
Antithrombin and mortality in severe 
pneumonia patients with sepsis-
associated disseminated intravascular 
coagulation: An observational nationwide 
study 
2014 IVA Historical 
VanDyke, R. D.; McPhail, G. L.; 
Huang, B.; Fenchel, M. C.; Amin, R. S.; 
Carle, A. C.; Chini, B. A.; Seid, M. 
Inhaled tobramycin effectively reduces 
FEV1 decline in cystic fibrosis an 
instrumental variables analysis 
2013 IVA Historical 
Wong, K.; Campitelli, M. A.; Stukel, 
T. A.; Kwong, J. C. 
Estimating influenza vaccine effectiveness 
in community-dwelling elderly patients 
using the instrumental variable analysis 
method 
2012 IVA Historical 
Chen, H.; Mehta, S.; Aparasu, R.; 
Patel, A.; Ochoa-Perez, M. 
Comparative effectiveness of 
monotherapy with mood stabilizers 
versus second generation (atypical) 
antipsychotics for the treatment of bipolar 
disorder in children and adolescents 
2014 IVA Historical + 
Time 
Newman, T. B.; Vittinghoff, E.; 
McCulloch, C. E. 
Efficacy of phototherapy for newborns 
with hyperbilirubinemia: a cautionary 
example of an instrumental variable 
analysis 
2012 IVA Historical + 
Time 
Ahern, T. P.; Pedersen, L.; 
Svaerke, C.; Rothman, K. J.; 
Sorensen, H. T.; Lash, T. L. 
The association between vitamin K 
antagonist therapy and site-specific 
cancer incidence estimated by using heart 
valve replacement as an instrumental 
variable 
2011 IVA Lagged 
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Cai, B.; Hennessy, S.; Flory, J. H.; Sha, 
D.;Ten Have, T. R.; Small, D. S. 
Simulation study of instrumental variable 
approaches with an application to a study 
of the antidiabetic effect of bezafibrate 
2012 IVA Lagged 
O'Malley, A. J. Instrumental variable specifications and 
assumptions for longitudinal analysis of 
mental health cost offsets 
2012 IVA Lagged 
Cawley, J.; Meyerhoefer, C. The medical care costs of obesity: An 
instrumental variables approach 
2012 IVA Other 
Groenwold, R. H.; Hak, E.; Klungel, 
O. H.; Hoes, A. W. 
Instrumental variables in influenza 
vaccination studies: mission impossible?! 
2010 IVA Other 
Kim, D.; Leigh, J. P. Estimating the effects of wages on obesity 2010 IVA Other 
Pirracchio, R.; Sprung, C.; Payen, 
D.; Chevret, S. 
Benefits of ICU admission in critically ill 
patients: whether instrumental variable 
methods or propensity scores should be 
used 
2011 IVA Other 
Selden, T. M.; Hudson, J. L. Access to care and utilization among 
children: Estimating the effects of public 
and private coverage 
2006 IVA Other 
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Slade, E. P.; Wissow, L. S.; Davis, M.; 
Abrams, M. T.; Dixon, L. B. 
Medicaid lapses and low-income young 
adults' receipt of outpatient mental health 
care after an inpatient stay 
2014 IVA Other 
Hay, J. W.; Lawler, E.; Yucel, K.; 
Guo, A.; Balzer, T.; Gaziano, J. M.; 
Scranton, R. E. 
Cost impact of diagnostic imaging for 
lower extremity peripheral vascular 
occlusive disease 
2009 IVA PScore 
(historical 
EHRs) 
Guo, J.; Konetzka, R. T.; Manning, W. 
G. 
The causal effects of home care use on 
institutional long-term care utilization 
and expenditures 
2015 IVA Randomisation 
Federspiel, J. J.; Stearns, S. C.; 
Sheridan, B. C.; Kuritzky, J. J.; D'Arcy, 
L. P.; Crespin, D. J.; Carey, T. S.; Rossi, 
J. S. 
Evaluating the effectiveness of a rapidly 
adopted cardiovascular technology with 
administrative data: The case of drug-
eluting stents for acute coronary 
syndromes 
2012 IVA Time 
Goyal, N.; Zubizarreta, J. R.; Small, D. 
S.; Lorch, S. A. 
Length of stay and readmission among 
late preterm infants: An instrumental 
variable approach 
2013 IVA Time 
Hollingsworth, J. M.; Norton, E. C.; 
Kaufman, S. R.; Smith, R. M.; Wolf Jr, 
J. S.; Hollenbeck, B. K. 
Medical expulsive therapy versus early 
endoscopic stone removal for acute renal 
colic: An instrumental variable analysis 
2013 IVA Time 
Johnston, K. M.; Gustafson, P.; Levy, 
A. R.; Grootendorst, P. 
Use of instrumental variables in the 
analysis of generalized linear models in 
the presence of unmeasured confounding 
with applications to epidemiological 
research 
2008 IVA Time 
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O'Donnell, H. C.; Colman, G.; 
Trachtman, R. A.; Velazco, N.; Racine, 
A. D. 
Impact of newborn follow-up visit timing 
on subsequent ED visits and hospital 
readmissions: AN instrumental variable 
analysis 
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